Results 51 to 60 of about 3,564 (173)
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations
, 2020 Background: Tezacaftor/ivacaftor is a CFTR modulator approved to treat people with cystic fibrosis (pwCF) who are homozygous (F/F) or heterozygous for the F508del-CFTR mutation and a residual function mutation (F/RF).
Campbell, Daniel +7 more
core +1 more source
Elexacaftor/Ivacaftor/Tezacaftor: First Approval
, 2019 Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding. Conflict of interest: Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article ...
Sheridan M. Hoy (4897468)
core +1 more source
Frontiers in Pharmacology, 2023 The prevalence of mental health disorders is high among people with Cystic Fibrosis. The psychological symptoms in CF are associated with poor adherence, worse treatment outcomes, and greater health utilization/cost.
Hisham Ibrahim +19 more
doaj +1 more source
Journal of Patient Experience, 2021 Cystic fibrosis (CF) is the leading genetic disease among Caucasians; however, advances in diagnosis and treatment have improved both quality and quantity of life for those affected.
Sigrid Ladores PhD, RN, PNP, CNE, FAAN +1 more
doaj +1 more source
Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis
Medicina, 2022 Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508del mutation in the transmembrane conductance regulator of the cystic fibrosis gene.
Federica Li Pomi +8 more
doaj +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40‐item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF‐specific minimal clinically important difference (MCID) has not been ...
Eugene Oh +34 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas +16 more
wiley +1 more source
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
European Respiratory Review, 2020 Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation ...
Michal Shteinberg +1 more
doaj +1 more source
Aplasia Cutis Congenita in the Setting of Maternal Cystic Fibrosis
Annals of Internal Medicine: Clinical Cases, 2022 Aplasia cutis congenita is a rare scalp defect. An affected neonate was delivered after in utero exposure beginning in the midtrimester to elexacaftor/tezacaftor/ivacaftor for maternal cystic fibrosis management. Although aplasia cutis congenita has many
Govind Kallumkal, Robert Egerman
doaj +1 more source
JPGN Reports, EarlyView.Abstract Objectives The efficacy of cystic fibrosis transmembrane conductance regulator (CFTR)‐modulator therapies in preventing or ameliorating cystic fibrosis liver disease (CFLD) by correcting CFTR in cholangiocytes is not well‐documented. This study aimed to assess liver function during CFTR‐modulators.
Laura Giugliano +12 more
wiley +1 more source